Abstract
Objective: To determine the effect of different treatment modalities on health outcomes in patients with osteoporosis.
Methodology: The study was conducted at a Medicare Cardiac and General Hospital and used a longitudinal design to follow up on participants from the Orthopedic Outpatient Department who were aged 35-60 or older and diagnosed with osteoporosis based on their DEXA scan T score. At the baseline, demographic data, medical history, physical activity, joint discomfort, periodontal pocket, and clinical attachment level were recorded. Intravenous bisphosphonate of 3 mg every 3 months, subcutaneous denosumab of 60mg every 6 months, along with calcium supplements (1200 mg/day) and vitamin D (600 IU/day) were administered. After a 1-year follow-up, the outcome variables were measured and compared to the baseline. The statistical analysis was performed using SPSS software and paired T-tests, and the Fischer exact test were used.
Results: The study included 200 participants, with mean age of 61.36±10.42 years and a mean BMI of 31.58±16.52. After 12 months of therapy, significant differences were observed in physical health outcomes, with the bisphosphonate group showing superior results in joint discomfort and physical activity compared to the denosumab group (p<0.001). Moreover, the bisphosphonate group demonstrated significantly higher clinical attachment level and shallower periodontal pocket depth, suggesting potential improvement in periodontal health (p<0.001).
Conclusion: Bisphosphonate treatment may be more effective than denosumab in reducing joint pain, overall health, and periodontal health in individuals with osteoporosis, underscoring the importance of personalized treatment strategies in clinical practice.

Key words: DEXA, osteoporosis. bisphosphonate, denosumab, physical & periodontal health.